Loading...

Glaspy John

TitleDirector
InstitutionUniversity of California Los Angeles
DepartmentSurgical Oncology
Address100 Medical Plaza Suite 550
CAMPUS - 699624
Phone(310) 794-4955
vCardDownload vCard
    Other Positions
    TitleAssociate Chief

    TitleAssociate Professor


    Collapse Research 
    Collapse Research Activities and Funding
    CLINICAL EVALUATION OF BIOLOGICAL RESPONSE MODIFIERS
    NIH/NCI N01CM007439Sep 30, 1980
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, Ratikan JA, Felix C, Hwang L, Faull KF, Sayre JW, Hurvitz S, Glaspy JA, Comin-Anduix B, Demaria S, Schaue D, McBride WH. Focal Irradiation and Systemic TGFß Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 Feb 23. PMID: 29476019.
      View in: PubMed
    2. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbé C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol. 2018 Jun 10; 36(17):1658-1667. PMID: 28981385.
      View in: PubMed
    3. Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer. 2017 11; 25(11):3295-3304. PMID: 28842778.
      View in: PubMed
    4. Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017 May; 18(5):654-662. PMID: 28314691.
      View in: PubMed
    5. de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov. 2017 06; 7(6):620-629. PMID: 28242752.
      View in: PubMed
    6. Blumenschein G, Chandler J, Garon EB, Waterhouse D, Goldman JW, Gunuganti VK, Boccia R, Spigel D, Glaspy J, Berry DA, Korytowsky B, Zhu J, Lin WH, Bennett K, Reynolds C. PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S307. PMID: 27969526.
      View in: PubMed
    7. Peterson DE, O'Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, Campbell-Baird C, Hronek J, Seery V, Divers J, Glaspy J, Schmidt BL, Meiller TF. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med. 2016 Aug; 5(8):1897-907. PMID: 27334013; PMCID: PMC4971919.
    8. Birgegård G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial. Pharmacotherapy. 2016 Apr; 36(4):402-14. PMID: 26927900.
      View in: PubMed
    9. Kaufman HL, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, Harrington K, Nemunaitis J, Zloza A, Wolf M, Senzer NN. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immunother Cancer. 2016; 4:12. PMID: 26981242; PMCID: PMC4791835.
    10. Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, Seja E, Kivork C, Siebert J, Kaplan-Lefko P, Wang X, Chmielowski B, Glaspy JA, Tumeh PC, Chodon T, Pe'er D, Comin-Anduix B. PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res. 2016 Mar; 4(3):194-203. PMID: 26787823; PMCID: PMC4775381 [Available on 03/01/17].
    11. Raftopoulos H, Laadem A, Hesketh PJ, Goldschmidt J, Gabrail N, Osborne C, Ali M, Sherman ML, Wang D, Glaspy JA, Puccio-Pick M, Zou J, Crawford J. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Support Care Cancer. 2016 Apr; 24(4):1517-25. PMID: 26370220; PMCID: PMC4766217.
    12. Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, Villanueva A, Ruchalski K, Glaspy JA, Kim KB, Hwu WJ, Ribas A. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer. 2015 Nov; 51(17):2689-97. PMID: 26364516; PMCID: PMC4821004 [Available on 11/01/16].
    13. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27; 515(7528):568-71. PMID: 25428505; PMCID: PMC4246418.
    14. Shander A, Goodnough LT, Javidroozi M, Auerbach M, Carson J, Ershler WB, Ghiglione M, Glaspy J, Lew I. Iron deficiency anemia--bridging the knowledge and practice gap. Transfus Med Rev. 2014 Jul; 28(3):156-66. PMID: 24931617.
      View in: PubMed
    15. Glaspy J. Current status of use of erythropoietic agents in cancer patients. Semin Thromb Hemost. 2014 Apr; 40(3):306-12. PMID: 24676903.
      View in: PubMed
    16. Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65. PMID: 24634374; PMCID: PMC4070853.
    17. Ribas A, Zhang W, Chang I, Shirai K, Ernstoff MS, Daud A, Cowey CL, Daniels G, Seja E, O'Laco E, Glaspy JA, Chmielowski B, Hill T, Joe AK, Grippo JF. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol. 2014 Apr; 54(4):368-74. PMID: 24374975.
      View in: PubMed
    18. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93. PMID: 24265155; PMCID: PMC3936420.
    19. Deitcher OR, Glaspy J, Gonzalez R, Sato T, Bedikian AY, Segarini K, Silverman J, Deitcher SR. High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):197-202. PMID: 24417913.
      View in: PubMed
    20. Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pintér T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bée V, Santana MJ, Miller DP, Lalla D, Slamon DJ. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist. 2013; 18(7):812-8. PMID: 23814044; PMCID: PMC3720634.
    21. Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med. 2013 Feb 14; 368(7):684-5. PMID: 23406047.
      View in: PubMed
    22. Vansteenkiste J, Wauters I, Elliott S, Glaspy J, Hedenus M. Chemotherapy-induced anemia: the story of darbepoetin alfa. Curr Med Res Opin. 2013 Apr; 29(4):325-37. PMID: 23323876.
      View in: PubMed
    23. Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan; 14(1):72-80. PMID: 23246022.
      View in: PubMed
    24. Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med. 2012 Nov 21; 10:236. PMID: 23171508; PMCID: PMC3543342.
    25. Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2012 Sep; 2(9):791-7. PMID: 22798288; PMCID: PMC3449158.
    26. Glaspy J. Update on safety of ESAs in cancer-induced anemia. J Natl Compr Canc Netw. 2012 May; 10(5):659-66. PMID: 22570294.
      View in: PubMed
    27. Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer. 2012 Jun; 76(3):478-85. PMID: 22277104.
      View in: PubMed
    28. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011; 6(12):e28973. PMID: 22194965; PMCID: PMC3237573.
    29. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 06; 365(14):1273-83. PMID: 21991949; PMCID: PMC3268553.
    30. Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, Mischel PS, Comin-Anduix B, Ribas A. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 2011 May 24; 9:76. PMID: 21609436; PMCID: PMC3152784.
    31. Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, Murray JL, Ibrahim NK. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011; 16(8):1092-100. PMID: 21572124; PMCID: PMC3228158.
    32. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011 Jun 15; 17(12):4101-9. PMID: 21558401; PMCID: PMC3117971.
    33. Glaspy JA. Darbepoetin alfa controversies, from dosage issues to safety concerns: the larger lesson. Oncology (Williston Park). 2011 Apr 30; 25(5):423-4. PMID: 21710839.
      View in: PubMed
    34. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 01; 29(10):1252-60. PMID: 21383283.
      View in: PubMed
    35. Glaspy JA. Randomized controlled trials of the erythroid-stimulating agents in cancer patients. Cancer Treat Res. 2011; 157:195-215. PMID: 21052958.
      View in: PubMed
    36. Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, Rodriguez MJ, Prieto VG, Glaspy JA, Oseguera DK, Hernandez J, Villanueva A, Chmielowski B, Mitsky P, Bercovici N, Wasserman E, Landais D, Ross MI. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Transl Med. 2010 Sep 27; 8:89. PMID: 20875102; PMCID: PMC2954849.
    37. Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer. 2010 Sep 15; 116(18):4227-37. PMID: 20549829.
      View in: PubMed
    38. Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, Glaspy JA, Essner R, Bollag G, Hirth P, Zhang C, Slamon DJ. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia. 2010 Aug; 12(8):637-49. PMID: 20689758; PMCID: PMC2915408.
    39. Hurvitz SA, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Ryba N, Lin LS, Wang H, Glaspy J, Slamon DJ, Kabbinavar F. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). Clin Breast Cancer. 2010 Aug 01; 10(4):307-12. PMID: 20705564.
      View in: PubMed
    40. Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010 Jul; 122(1):181-8. PMID: 20361252.
      View in: PubMed
    41. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010 Jan 19; 102(2):301-15. PMID: 20051958; PMCID: PMC2816662.
    42. Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, Jungnelius JU, Glaspy J. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer. 2010 Jan 01; 116(1):146-54. PMID: 19862820.
      View in: PubMed
    43. Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res. 2009 Dec 01; 15(23):7116-8. PMID: 19934296.
      View in: PubMed
    44. Glaspy J, Atkins MB, Richards JM, Agarwala SS, O'Day S, Knight RD, Jungnelius JU, Bedikian AY. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer. 2009 Nov 15; 115(22):5228-36. PMID: 19728370.
      View in: PubMed
    45. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R, Nemunaitis JJ. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009 Dec 01; 27(34):5763-71. PMID: 19884534.
      View in: PubMed
    46. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009 Oct 01; 15(19):6267-76. PMID: 19789309; PMCID: PMC2765061.
    47. Glaspy J. Hematology: ESAs to treat anemia--balancing the risks and benefits. Nat Rev Clin Oncol. 2009 Sep; 6(9):500-2. PMID: 19707239.
      View in: PubMed
    48. Naeim A, Friedman L, Whitlock KB, Pasta DJ, Elkin EP, Lubeck DP, Viswanathan HN, Glaspy J. Patterns of care in community-based oncology practices for anemia associated with myelosuppressive chemotherapy. J Oncol Pract. 2009 Sep; 5(5):236-43. PMID: 20856735; PMCID: PMC2790673.
    49. Glaspy J, Ribas A, Chmielowski B. Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it? J Clin Oncol. 2009 Jun 20; 27(18):2896-7. PMID: 19433677.
      View in: PubMed
    50. Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009 Jun 10; 27(17):2838-47. PMID: 19380447.
      View in: PubMed
    51. Glaspy JA, Charu V, Luo D, Moyo V, Kamin M, Wilhelm FE. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms. Cancer. 2009 Mar 01; 115(5):1121-31. PMID: 19170225.
      View in: PubMed
    52. Glaspy JA. Erythropoietin in cancer patients. Annu Rev Med. 2009; 60:181-92. PMID: 18980468.
      View in: PubMed
    53. Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res. 2009 Jan 01; 15(1):390-9. PMID: 19118070.
      View in: PubMed
    54. Glaspy JA. Erythropoiesis-stimulating agents in oncology. J Natl Compr Canc Netw. 2008 Jul; 6(6):565-75. PMID: 18597710.
      View in: PubMed
    55. Aapro MS, Birgegård G, Bokemeyer C, Cornes P, Foubert J, Gascon P, Glaspy J, Hellström-Lindberg E, Link H, Ludwig H, Osterborg A, Repetto L, Soubeyran P. Erythropoietins should be used according to guidelines. Lancet Oncol. 2008 May; 9(5):412-3. PMID: 18452853.
      View in: PubMed
    56. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008 May 01; 6:22. PMID: 18452610; PMCID: PMC2412852.
    57. Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother. 2008 Apr; 31(3):294-309. PMID: 18317358; PMCID: PMC3651040.
    58. Rodgers GM, Auerbach M, Cella D, Chertow GM, Coyne DW, Glaspy JA, Henry DH. High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol. 2008 May; 19(5):833-4. PMID: 18369084.
      View in: PubMed
    59. Smith RE, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008 Mar 01; 26(7):1040-50. PMID: 18227526.
      View in: PubMed
    60. Rubin RJ, Glaspy JA, Adams JL, Mafilios MS, Wang SM, Viswanathan HN, Kallich JD. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective. J Med Econ. 2008; 11(2):199-213. PMID: 19450080.
      View in: PubMed
    61. Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Oncologist. 2007 Oct; 12(10):1253-63. PMID: 17962619.
      View in: PubMed
    62. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007 May 05; 369(9572):1502-4. PMID: 17482969.
      View in: PubMed
    63. Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, Gomez-Navarro J, Ribas A. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am J Ophthalmol. 2007 Jun; 143(6):958-969. PMID: 17434437.
      View in: PubMed
    64. Hirsh V, Glaspy J, Mainwaring P, Manegold C, Ramlau R, Eid JE. Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Trials. 2007 Mar 06; 8:8. PMID: 17341293; PMCID: PMC1831793.
    65. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy JA, Aronson WJ. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res. 2006 Aug 01; 12(15):4662-70. PMID: 16899616; PMCID: PMC3410648.
    66. Glaspy J. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia. Oncology (Williston Park). 2006 Jul; 20(8 Suppl 6):29-32. PMID: 16925109.
      View in: PubMed
    67. Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol. 2006 May 20; 24(15):2290-7. PMID: 16710026.
      View in: PubMed
    68. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res. 2006 May 01; 12(9):2817-25. PMID: 16675576.
      View in: PubMed
    69. Schumacher LY, Vo DD, Garban HJ, Comin-Anduix B, Owens SK, Dissette VB, Glaspy JA, McBride WH, Bonavida B, Economou JS, Ribas A. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol. 2006 Apr 15; 176(8):4757-65. PMID: 16585569.
      View in: PubMed
    70. Lyman GH, Glaspy J. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer. 2006 Jan 01; 106(1):223-33. PMID: 16331597.
      View in: PubMed
    71. Comin-Anduix B, Gualberto A, Glaspy JA, Seja E, Ontiveros M, Reardon DL, Renteria R, Englahner B, Economou JS, Gomez-Navarro J, Ribas A. Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res. 2006 Jan 01; 12(1):107-16. PMID: 16397031.
      View in: PubMed
    72. Glaspy JA. Cancer patient survival and erythropoietin. J Natl Compr Canc Netw. 2005 Nov; 3(6):796-804. PMID: 16316615.
      View in: PubMed
    73. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005 Dec 10; 23(35):8968-77. PMID: 16204013.
      View in: PubMed
    74. Glaspy JA. Every-three-week erythropoietic support during chemotherapy for cancer: current status and future issues. Support Cancer Ther. 2005 Oct 01; 3(1):16-20. PMID: 18632430.
      View in: PubMed
    75. Crawford J, Glaspy JA, Stoller RG, Tomita DK, Vincent ME, McGuire BW, Ozer H. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther. 2005 Oct 01; 3(1):36-46. PMID: 18632435.
      View in: PubMed
    76. Ribas A, Vo DD, Weeks DL, Comin-Anduix B, Schumacher LY, Garban HJ, McLean C, Yang J, Dissette VB, Peraza P, Owens SK, McBride WH, Glaspy JA, Economou JS. Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice. Cancer Immunol Immunother. 2006 Jun; 55(6):663-71. PMID: 16133107.
      View in: PubMed
    77. Glaspy JA. The development of erythropoietic agents in oncology. Expert Opin Emerg Drugs. 2005 Aug; 10(3):553-67. PMID: 16083329.
      View in: PubMed
    78. Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS, Ribas A. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer Gene Ther. 2005 Jun; 12(6):516-27. PMID: 15775996.
      View in: PubMed
    79. Glaspy J, Henry D, Patel R, Tchekmedyian S, Applebaum S, Berdeaux D, Lloyd R, Berg R, Austin M, Rossi G. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer. 2005 May; 41(8):1140-9. PMID: 15911237.
      View in: PubMed
    80. Glaspy J, Beguin Y. Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon). Oncology. 2005; 69 Suppl 2:8-16. PMID: 16244505.
      View in: PubMed
    81. Berndt E, Kallich J, McDermott A, Xu X, Lee H, Glaspy J. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics. 2005; 23(5):505-14. PMID: 15896101.
      View in: PubMed
    82. Glaspy JA. Entering a new era in the management of tumor-associated involution. J Support Oncol. 2005 Jan-Feb; 3(1):51-2. PMID: 15724945.
      View in: PubMed
    83. Glaspy J. Phase III clinical trials with darbepoetin: implications for clinicians. Best Pract Res Clin Haematol. 2005; 18(3):407-16. PMID: 15792914.
      View in: PubMed
    84. Chamras H, Barsky SH, Ardashian A, Navasartian D, Heber D, Glaspy JA. Novel interactions of vitamin E and estrogen in breast cancer. Nutr Cancer. 2005; 52(1):43-8. PMID: 16091003.
      View in: PubMed
    85. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN, McBride WH, Economou JS, Butterfield LH. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother. 2004 Sep-Oct; 27(5):354-67. PMID: 15314544.
      View in: PubMed
    86. Gordon LK, Ribas A, Nusinowitz S, Butterfield LH, Glaspy JA, Economou JS, Straatsma BR. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. Control Clin Trials. 2004 Aug; 25(4):400-7. PMID: 15296814.
      View in: PubMed
    87. Ribas A, Wargo JA, Comin-Anduix B, Sanetti S, Schumacher LY, McLean C, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol. 2004 Apr 15; 172(8):4762-9. PMID: 15067052.
      View in: PubMed
    88. Glaspy J, Dunst J. Can erythropoietin therapy improve survival? Oncology. 2004; 67 Suppl 1:5-11. PMID: 15486447.
      View in: PubMed
    89. Glaspy JA. Hematopoietic management in oncology practice. Part 2. Erythropoietic factors. Oncology (Williston Park). 2003 Dec; 17(12):1724-30; discussion 1731-2, 1735, 1739. PMID: 14723012.
      View in: PubMed
    90. Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, Seja E, Todd K, Glaspy JA, McBride WH, Economou JS. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5902-8. PMID: 14676113.
      View in: PubMed
    91. Glaspy JA. Hematopoietic management in oncology practice. Part 1. Myeloid growth factors. Oncology (Williston Park). 2003 Nov; 17(11):1593-603. PMID: 14682110.
      View in: PubMed
    92. Smith JR, Glaspy JA, Tchekmedyian NS, Austin MD, Kallich JD. Hemoglobin increase is associated with improved health-related quality of life in patients with cancer not receiving chemotherapy. Support Cancer Ther. 2003 Oct 01; 1(1):49-54. PMID: 18628131.
      View in: PubMed
    93. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003 Jun 15; 21(12):2415-32. PMID: 12805342.
      View in: PubMed
    94. Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther. 2003 Jun; 25(6):1786-805. PMID: 12860499.
      View in: PubMed
    95. O'Day SJ, Agarwala SS, Naredi P, Kass CL, Gehlsen KR, Glaspy J. Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis. Melanoma Res. 2003 Jun; 13(3):307-11. PMID: 12777988.
      View in: PubMed
    96. Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep. 2003 May-Jun; 10(3):715-24. PMID: 12684649.
      View in: PubMed
    97. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006. PMID: 12637463.
      View in: PubMed
    98. Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer. 2003 Mar 01; 97(5):1312-20. PMID: 12599240.
      View in: PubMed
    99. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 2003 Mar; 9(3):998-1008. PMID: 12631598.
      View in: PubMed
    100. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1751-6. PMID: 12578976; PMCID: PMC149905.
    101. Kubista E, Glaspy J, Holmes FA, Green MD, Hackett J, Neumann T. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer. 2003 Feb; 3(6):391-8. PMID: 12636878.
      View in: PubMed
    102. Beusterien KM, Ackerman SJ, Plante K, Glaspy J, Naredi P, Wood D, Gehlsen K, Agarwala SS. The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma. Support Care Cancer. 2003 May; 11(5):304-12. PMID: 12720074.
      View in: PubMed
    103. Chamras H, Ardashian A, Heber D, Glaspy JA. Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation. J Nutr Biochem. 2002 Dec; 13(12):711-716. PMID: 12550055.
      View in: PubMed
    104. Catlin DH, Breidbach A, Elliott S, Glaspy J. Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem. 2002 Nov; 48(11):2057-9. PMID: 12406997.
      View in: PubMed
    105. Ribas A, Amarnani SN, Buga GM, Butterfield LH, Dissette VB, McBride WH, Glaspy JA, Ignarro LJ, Economou JS. Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines. Cancer Gene Ther. 2002 Nov; 9(11):875-83. PMID: 12386826.
      View in: PubMed
    106. Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Williston Park). 2002 Oct; 16(10 Suppl 11):23-9. PMID: 12435170.
      View in: PubMed
    107. Vansteenkiste J, Poulsen E, Rossi G, Glaspy J. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations. Oncology (Williston Park). 2002 Oct; 16(10 Suppl 11):45-55. PMID: 12435173.
      View in: PubMed
    108. Glaspy JA. The potential for anemia treatment to improve survival in cancer patients. Oncology (Williston Park). 2002 Sep; 16(9 Suppl 10):35-40. PMID: 12380953.
      View in: PubMed
    109. Glaspy JA. Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency. Oncology (Williston Park). 2002 Sep; 16(9 Suppl 10):71-7. PMID: 12380957.
      View in: PubMed
    110. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002 Aug 15; 95(4):888-95. PMID: 12209734.
      View in: PubMed
    111. Shen J, Andersen R, Albert PS, Wenger N, Glaspy J, Cole M, Shekelle P. Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med. 2002 Aug 13; 2:8. PMID: 12175424; PMCID: PMC122074.
    112. Langer CJ, Choy H, Glaspy JA, Colowick A. Standards of care for anemia management in oncology: focus on lung carcinoma. Cancer. 2002 Aug 01; 95(3):613-23. PMID: 12209755.
      View in: PubMed
    113. Paquette RL, Hsu N, Said J, Mohammed M, Rao NP, Shih G, Schiller G, Sawyers C, Glaspy JA. Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia. 2002 Aug; 16(8):1484-9. PMID: 12145689.
      View in: PubMed
    114. Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O'Byrne J, Rossi G, Colowick AB. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer. 2002 Jul 29; 87(3):268-76. PMID: 12177793; PMCID: PMC2364226.
    115. Middleton M, Sarno M, Agarwala SS, Glaspy J, Laurent A, McMasters K, Naredi P, O'Day S, Whitman E, Danson S, Cosford R, Gehlsen K. Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2. J Clin Pharmacol. 2002 Jul; 42(7):774-81. PMID: 12092744.
      View in: PubMed
    116. Glaspy JA. Therapeutic options in the management of renal cell carcinoma. Semin Oncol. 2002 Jun; 29(3 Suppl 7):41-6. PMID: 12068388.
      View in: PubMed
    117. Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA. Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery. Exp Hematol. 2002 Apr; 30(4):374-80. PMID: 11937274.
      View in: PubMed
    118. Demetri GD, Gabrilove JL, Blasi MV, Hill RJ, Glaspy J. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer. 2002 Apr; 3(1):45-51. PMID: 12020395.
      View in: PubMed
    119. Crawford J, Demetri GD, Gabrilove JL, Blasi MV, Sarokhan BJ, Glaspy J. Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer. 2002 Feb; 3(3):180-90. PMID: 14662041.
      View in: PubMed
    120. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Cancer immunotherapy using gene-modified dendritic cells. Curr Gene Ther. 2002 Feb; 2(1):57-78. PMID: 12108974.
      View in: PubMed
    121. Bagga D, Anders KH, Wang HJ, Glaspy JA. Long-chain n-3-to-n-6 polyunsaturated fatty acid ratios in breast adipose tissue from women with and without breast cancer. Nutr Cancer. 2002; 42(2):180-5. PMID: 12416257.
      View in: PubMed
    122. Glaspy J, Degos L, Dicato M, Demetri GD. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist. 2002; 7(2):126-35. PMID: 11961196.
      View in: PubMed
    123. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, Meyskens F, Hellstrand K, Wood D, Kirkwood JM, Gehlsen KR, Naredi P. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):125-33. PMID: 11773161.
      View in: PubMed
    124. Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, Glaspy JA, McBride WH, Economou JS. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res. 2001 Dec 15; 61(24):8782-6. PMID: 11751399.
      View in: PubMed
    125. Ribas A, Butterfield LH, Amarnani SN, Dissette VB, Kim D, Meng WS, Miranda GA, Wang HJ, McBride WH, Glaspy JA, Economou JS. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells. Cancer Res. 2001 Dec 15; 61(24):8787-93. PMID: 11751400.
      View in: PubMed
    126. Aronson WJ, Glaspy JA, Reddy ST, Reese D, Heber D, Bagga D. Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology. 2001 Aug; 58(2):283-8. PMID: 11489728.
      View in: PubMed
    127. Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, Faull K, Glaspy JA, McBride WH, Economou JS. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol. 2001 Apr 15; 166(8):5300-8. PMID: 11290817.
      View in: PubMed
    128. Andrews KJ, Ribas A, Butterfield LH, Vollmer CM, Eilber FC, Dissette VB, Nelson SD, Shintaku P, Mekhoubad S, Nakayama T, Taniguchi M, Glaspy JA, McBride WH, Economou JS. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells. Cancer Res. 2000 Nov 15; 60(22):6457-64. PMID: 11103813.
      View in: PubMed
    129. Meng WS, Butterfield LH, Ribas A, Heller JB, Dissette VB, Glaspy JA, McBride WH, Economou JS. Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. Mol Immunol. 2000 Nov; 37(16):943-50. PMID: 11395133.
      View in: PubMed
    130. Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA. Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. Blood. 2000 Oct 01; 96(7):2385-90. PMID: 11001888.
      View in: PubMed
    131. Glaspy JA. Hematologic supportive care of the critically ill cancer patient. Semin Oncol. 2000 Jun; 27(3):375-83. PMID: 10864224.
      View in: PubMed
    132. Bagga D, Anders KH, Wang HJ, Roberts E, Glaspy JA. Organochlorine pesticide content of breast adipose tissue from women with breast cancer and control subjects. J Natl Cancer Inst. 2000 May 03; 92(9):750-3. PMID: 10793112.
      View in: PubMed
    133. Ribas A, Butterfield LH, Hu B, Dissette VB, Meng WS, Koh A, Andrews KJ, Lee M, Amar SN, Glaspy JA, McBride WH, Economou JS. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. Cancer Res. 2000 Apr 15; 60(8):2218-24. PMID: 10786687.
      View in: PubMed
    134. Ribas A, Butterfield LH, Hu B, Dissette VB, Chen AY, Koh A, Amarnani SN, Glaspy JA, McBride WH, Economou JS. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother. 2000 Jan; 23(1):59-66. PMID: 10687138.
      View in: PubMed
    135. Ribas A, Butterfield LH, McBride WH, Dissette VB, Koh A, Vollmer CM, Hu B, Chen AY, Glaspy JA, Economou JS. Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells. Cancer Gene Ther. 1999 Nov-Dec; 6(6):523-36. PMID: 10608349.
      View in: PubMed
    136. Vollmer CM, Ribas A, Butterfield LH, Dissette VB, Andrews KJ, Eilber FC, Montejo LD, Chen AY, Hu B, Glaspy JA, McBride WH, Economou JS. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res. 1999 Sep 01; 59(17):4369-74. PMID: 10485485.
      View in: PubMed
    137. Vollmer CM, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Economou JS. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res. 1999 Jul 01; 59(13):3064-7. PMID: 10397245.
      View in: PubMed
    138. Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, Lee E, Glaspy JA, McBride WH, Economou JS. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res. 1999 Jul 01; 59(13):3134-42. PMID: 10397256.
      View in: PubMed
    139. Glaspy JA. Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Bone Marrow Transplant. 1999 May; 23 Suppl 2:S21-7. PMID: 10335873.
      View in: PubMed
    140. Shpall EJ, Wheeler CA, Turner SA, Yanovich S, Brown RA, Pecora AL, Shea TC, Mangan KF, Williams SF, LeMaistre CF, Long GD, Jones R, Davis MW, Murphy-Filkins R, Parker WR, Glaspy JA. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood. 1999 Apr 15; 93(8):2491-501. PMID: 10194427.
      View in: PubMed
    141. Ribas A, Bui LA, Butterfield LH, Vollmer CM, Jilani SM, Dissette VB, Glaspy JA, McBride WH, Economou JS. Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities. Anticancer Res. 1999 Mar-Apr; 19(2A):1165-70. PMID: 10368670.
      View in: PubMed
    142. Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB, Lau R, Gamradt SC, Glaspy JA, McBride WH, Mukherji B, Economou JS. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol. 1998 Nov 15; 161(10):5607-13. PMID: 9820539.
      View in: PubMed
    143. Jilani SM, Glaspy JA. Impact of epoetin alfa in chemotherapy-associated anemia. Semin Oncol. 1998 Oct; 25(5):571-6. PMID: 9783596.
      View in: PubMed
    144. Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, Glaspy JA. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol. 1998 Sep; 64(3):358-67. PMID: 9738663.
      View in: PubMed
    145. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998 Aug; 16(8):2659-71. PMID: 9704716.
      View in: PubMed
    146. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med. 1998 Mar; 39(3):431-5. PMID: 9529287.
      View in: PubMed
    147. Glick HA, Shpall EJ, LeMaistre CF, McCarron TJ, Lu ZJ, Erder MH, Glaspy JA. Empirical criteria for the selection of quality-of-life instruments for the evaluation of peripheral blood progenitor cell transplantation. Int J Technol Assess Health Care. 1998; 14(3):419-30. PMID: 9780529.
      View in: PubMed
    148. Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant. 1998; 4(2):84-92. PMID: 9763111.
      View in: PubMed
    149. Bui LA, Butterfield LH, Kim JY, Ribas A, Seu P, Lau R, Glaspy JA, McBride WH, Economou JS. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum Gene Ther. 1997 Dec 10; 8(18):2173-82. PMID: 9449371.
      View in: PubMed
    150. Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM, Turner SA, Lill M, Chap L, Jones R, Wiers MD, Sheridan WP, McNiece IK. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood. 1997 Oct 15; 90(8):2939-51. PMID: 9376574.
      View in: PubMed
    151. Capone SL, Bagga D, Glaspy JA. Relationship between omega-3 and omega-6 fatty acid ratios and breast cancer. Nutrition. 1997 Sep; 13(9):822-4. PMID: 9290101.
      View in: PubMed
    152. Bagga D, Capone S, Wang HJ, Heber D, Lill M, Chap L, Glaspy JA. Dietary modulation of omega-3/omega-6 polyunsaturated fatty acid ratios in patients with breast cancer. J Natl Cancer Inst. 1997 Aug 06; 89(15):1123-31. PMID: 9262250.
      View in: PubMed
    153. Ribas A, Butterfield LH, McBride WH, Jilani SM, Bui LA, Vollmer CM, Lau R, Dissette VB, Hu B, Chen AY, Glaspy JA, Economou JS. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res. 1997 Jul 15; 57(14):2865-9. PMID: 9230191.
      View in: PubMed
    154. Toombs CF, Young CH, Glaspy JA, Varnum BC. Megakaryocyte growth and development factor (MGDF) moderately enhances in-vitro platelet aggregation. Thromb Res. 1995 Oct 01; 80(1):23-33. PMID: 8578535.
      View in: PubMed
    155. Schmid I, Baldwin GC, Jacobs EL, Isacescu V, Neagos N, Giorgi JV, Glaspy JA. Alterations in phenotype and cell-surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM-CSF or rhGM-CSF. Cytometry. 1995 Jun 15; 22(2):103-10. PMID: 7587740.
      View in: PubMed
    156. Yao WJ, Hoh CK, Hawkins RA, Glaspy JA, Weil JA, Lee SJ, Maddahi J, Phelps ME. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med. 1995 May; 36(5):794-9. PMID: 7738650.
      View in: PubMed
    157. Lill MC, Lynch M, Fraser JK, Chung GY, Schiller G, Glaspy JA, Souza L, Baldwin GC, Gasson JC. Production of functional myeloid cells from CD34-selected hematopoietic progenitor cells using a clinically relevant ex vivo expansion system. Stem Cells. 1994 Nov; 12(6):626-37. PMID: 7533581.
      View in: PubMed
    158. Glaspy JA, Chap L. The clinical application of recombinant erythropoietin in the HIV-infected patient. Hematol Oncol Clin North Am. 1994 Oct; 8(5):945-59. PMID: 7852217.
      View in: PubMed
    159. Glaspy JA, Jakway J. Cost considerations in therapy with myeloid growth factors. Am J Hosp Pharm. 1993 Jul; 50(7 Suppl 3):S19-26. PMID: 7689789.
      View in: PubMed
    160. Glaspy JA, Bleecker G, Crawford J, Stoller R, Strauss M. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer. 1993; 29A Suppl 7:S23-30. PMID: 7508727.
      View in: PubMed
    161. Glaspy JA. Hemostatic abnormalities in multiple myeloma and related disorders. Hematol Oncol Clin North Am. 1992 Dec; 6(6):1301-14. PMID: 1452513.
      View in: PubMed
    162. Messa C, Choi Y, Hoh CK, Jacobs EL, Glaspy JA, Rege S, Nitzsche E, Huang SC, Phelps ME, Hawkins RA. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr. 1992 Sep-Oct; 16(5):684-9. PMID: 1522257.
      View in: PubMed
    163. Glaspy JA, Golde DW. Granulocyte colony-stimulating factor (G-CSF): preclinical and clinical studies. Semin Oncol. 1992 Aug; 19(4):386-94. PMID: 1380729.
      View in: PubMed
    164. Glaspy JA, Souza L, Scates S, Narachi M, Blatt L, Ambersley J, Golde DW. Treatment of hairy cell leukemia with granulocyte colony-stimulating factor and recombinant consensus interferon or recombinant interferon-alpha-2b. J Immunother (1991). 1992 Apr; 11(3):198-208. PMID: 1381218.
      View in: PubMed
    165. Fazio MT, Glaspy JA. The impact of granulocyte colony-stimulating factor on quality of life in patients with severe chronic neutropenia. Oncol Nurs Forum. 1991 Nov-Dec; 18(8):1411-4. PMID: 1722310.
      View in: PubMed
    166. Roberts RL, Szelc CM, Scates SM, Boyd MT, Soderstrom KM, Davis MW, Glaspy JA. Neutropenia in an extremely premature infant treated with recombinant human granulocyte colony-stimulating factor. Am J Dis Child. 1991 Jul; 145(7):808-12. PMID: 1711773.
      View in: PubMed
    167. Miles SA, Mitsuyasu RT, Moreno J, Baldwin G, Alton NK, Souza L, Glaspy JA. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood. 1991 May 15; 77(10):2109-17. PMID: 1709368.
      View in: PubMed
    168. Glaspy JA, Golde DW. Clinical trials of myeloid growth factors. Exp Hematol. 1990 Nov; 18(10):1137-41. PMID: 1698650.
      View in: PubMed
    169. Glaspy JA, Golde DW. The colony-stimulating factors: biology and clinical use. Oncology (Williston Park). 1990 Sep; 4(9):25-32; discussion 32-4. PMID: 2145019.
      View in: PubMed
    170. Miles SA, Mitsuyasu RT, Lee K, Moreno J, Alton K, Egrie JC, Souza L, Glaspy JA. Recombinant human granulocyte colony-stimulating factor increases circulating burst forming unit-erythron and red blood cell production in patients with severe human immunodeficiency virus infection. Blood. 1990 Jun 01; 75(11):2137-42. PMID: 1693297.
      View in: PubMed
    171. Glaspy JA, Ambersley JM. The promise of colony-stimulating factors in clinical practice. Oncol Nurs Forum. 1990 Jan-Feb; 17(1 Suppl):20-4. PMID: 1689043.
      View in: PubMed
    172. Glaspy JA, Baldwin GC, Robertson PA, Souza L, Vincent M, Ambersley J, Golde DW. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med. 1988 Nov 15; 109(10):789-95. PMID: 2461131.
      View in: PubMed
    John's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _